Phase 1/2Recruiting
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
A Randomized, Placebo-Controlled, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, and Pharmacokinetics of IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
- Sponsor
- Ingenia Therapeutics INC (Industry)
- Enrolment
- 94 planned
- Conditions
- Healthy Volunteers; Chronic Kidney Disease
- Interventions
- IGT-303; Placebo
- Ages
- adults, older adults
- Registry
- NCT07231679
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.
Primary outcomes
- Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs)
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started